Joshua Jennings
Stock Analyst at TD Cowen
(3.32)
# 987
Out of 5,182 analysts
82
Total ratings
47.44%
Success rate
4%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $3.5 → $1 | $0.85 | +17.99% | 4 | Mar 30, 2026 | |
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $5.16 | +16.28% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $23.03 | +47.63% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $58.45 | +71.09% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $227.79 | +9.75% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $82.28 | +17.89% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $3.90 | +284.62% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $20.80 | -3.85% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $7.18 | +108.91% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $59.32 | +41.60% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.68 | +164.08% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $182.87 | +77.18% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $101.26 | +18.51% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $82.80 | +43.72% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $35.65 | +68.30% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $74.16 | +7.87% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $4.32 | +941.67% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $17.94 | +122.97% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $321.43 | +24.44% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $64.40 | -6.83% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $18.63 | +82.50% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.69 | +169.06% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $16.56 | +50.97% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $93.86 | +38.50% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.86 | +168.82% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $81.90 | +42.86% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $9.35 | +28.34% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $149.52 | +83.92% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $9.96 | +176.17% | 3 | Sep 5, 2018 |
Humacyte
Mar 30, 2026
Maintains: Buy
Price Target: $3.5 → $1
Current: $0.85
Upside: +17.99%
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $5.16
Upside: +16.28%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $23.03
Upside: +47.63%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $58.45
Upside: +71.09%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $227.79
Upside: +9.75%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $82.28
Upside: +17.89%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $3.90
Upside: +284.62%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $20.80
Upside: -3.85%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $7.18
Upside: +108.91%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $59.32
Upside: +41.60%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.68
Upside: +164.08%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $182.87
Upside: +77.18%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $101.26
Upside: +18.51%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $82.80
Upside: +43.72%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $35.65
Upside: +68.30%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $74.16
Upside: +7.87%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $4.32
Upside: +941.67%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $17.94
Upside: +122.97%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $321.43
Upside: +24.44%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $64.40
Upside: -6.83%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $18.63
Upside: +82.50%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.69
Upside: +169.06%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $16.56
Upside: +50.97%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $93.86
Upside: +38.50%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.86
Upside: +168.82%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $81.90
Upside: +42.86%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $9.35
Upside: +28.34%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $149.52
Upside: +83.92%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $9.96
Upside: +176.17%